Key result
Adjuvant therapy following surgery significantly improved survival compared to surgery alone and other treatment modalities in patients with primary lung carcinosarcoma (p=0.0055).
Why the study?
Primary lung carcinosarcoma has an incompletely elucidated pathogenesis, resistance to conventional therapy, and lacks an established standard treatment protocol.
Does adjuvant therapy following surgery improve survival in patients with primary lung carcinosarcoma compared to surgery alone?
Does adjuvant therapy following surgery improve survival in patients with primary lung carcinosarcoma compared to surgery alone?
Adjuvant therapy following complete surgical resection may be the most effective strategy to enhance prognosis in patients with primary lung carcinosarcoma.
Answers are grounded in this paper and cite their sources.
Management of lung carcinosarcoma remains extrapolated from other tumors; leaves open dedicated prospective trials to define standards.
BACKGROUND: Primary lung carcinosarcoma, characterized by the presence of both carcinoma and sarcoma components, is a rare soft tissue malignancy. Its pathogenesis remains incompletely elucidated, and it exhibits significant resistance to conventional therapeutic interventions, resulting in a dismal prognosis. Consequently, there is currently no established standard treatment protocol for lung carcinosarcoma, leading most clinicians to draw upon their experiences with other tumor types when formulating treatment strategies. CASE DESCRIPTION: A 56-year-old non-smoking male presented with a progressively enlarging mass in the right cervical region, The diagnosis of lung carcinosarcoma was definitively confirmed through CT-guided biopsy. First-line immunotherapy combined with targeted therapy was ineffective; second-line chemotherapy was effective, chest CT revealed the disappearance of enlarged lymph nodes in the retrosternal area and a significant reduction of pulmonary lesions, but showed signs of brain metastasis. the patient passed away at home on June 27th, 2023 due to sudden onset dyspnea accompanied by loss of consciousness. LITERATURE REVIEW: A comprehensive literature search for lung carcinosarcoma was conducted across four databases, including PubMed/MEDLINE, Web of Science, Cochrane Library, and Embase, covering the period from 1968 to 2023. A total of 48 patients were included for analysis. Further survival analysis revealed a median survival time of 18 months; adjuvant therapy following surgery significantly improved survival compared to surgery alone and other treatment modalities. CONCLUSION: Lung carcinosarcoma is an exceptionally rare malignant neoplasm of the lung, and definitive treatment protocols remain elusive. The most effective strategy to enhance prognosis may still entail complete surgical resection of the lesions in conjunction with adjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a review in Primary lung carcinosarcoma (n=48). Adjuvant therapy following surgery vs. Surgery alone and other treatments was evaluated on Overall survival (p=0.0055). Adjuvant therapy following surgery significantly improved survival compared to surgery alone and other treatment modalities in patients with primary lung carcinosarcoma (p=0.0055).
Synapse has enriched 10 related papers. Consider them for comparative context: